News
JAZZ
100.50
-1.52%
-1.55
Buy Rating Maintained for Jazz Pharmaceuticals Amid Overreaction to Tariff Concerns and Strategic Mitigation Plans
TipRanks · 2d ago
Arcturus Gets FDA's Fast Track Tag for Influenza Vaccine Candidate
Barchart · 2d ago
Where Jazz Pharmaceuticals Stands With Analysts
Benzinga · 3d ago
Jazz (JAZZ) Moves 7.1% Higher: Will This Strength Last?
NASDAQ · 3d ago
TG Therapeutics Shares Rise Almost 30% in 3 Months: Here's Why
Barchart · 3d ago
Analysts’ Top Healthcare Picks: BridgeBio Pharma (BBIO), Praxis Precision Medicines (PRAX)
TipRanks · 3d ago
Should John Hancock Multifactor Small Cap ETF (JHSC) Be on Your Investing Radar?
NASDAQ · 3d ago
Trump's Tariffs Circle Pharma Industry: Who It Affects And How It May Play Out
Seeking Alpha · 4d ago
Jazz Pharma inks $145M deal to resolve Xyrem antitrust claims
Seeking Alpha · 4d ago
Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Stock's 26% Dive Might Signal An Opportunity But It Requires Some Scrutiny
Simply Wall St · 4d ago
JAZZ Pharmaceuticals Stock Trades Near 52-Week Low: Time to Buy or Sell?
Barchart · 4d ago
Jazz Pharmaceuticals Enters Preliminary $145M Class Settlement Agreement To Resolve Antitrust And Consumer Protection Claims Related To Patent Litigation Settlements For Xyrem, Expected To Record Pre-Tax Charge In Q1 2025
Benzinga · 5d ago
JAZZ PHARMACEUTICALS PLC - TO RECORD $145 MILLION PRE-TAX CHARGE IN Q1 2025 - SEC FILING
Reuters · 5d ago
AZN Gets EU Nod for Expanded Use of Two Separate Cancer Drugs
NASDAQ · 6d ago
5 High ROE Stocks to Buy as Markets Face Tariff Bloodbath
NASDAQ · 6d ago
Is John Hancock Multifactor Small Cap ETF (JHSC) a Strong ETF Right Now?
NASDAQ · 6d ago
Weekly Report: what happened at JAZZ last week (0331-0404)?
Weekly Report · 6d ago
European pharma evaluates ways to mitigate impact of tariff uncertainty
Seeking Alpha · 04/04 17:58
AMGN's Uplizna Gets FDA Nod for 2nd Rare Autoimmune Disease Indication
NASDAQ · 04/04 17:10
SNY's Rilzabrutinib Gets FDA's Orphan Drug Tag for Two Rare Diseases
NASDAQ · 04/03 15:27
More
Webull provides a variety of real-time JAZZ stock news. You can receive the latest news about Jazz Pharmaceuticals Plc through multiple platforms. This information may help you make smarter investment decisions.
About JAZZ
More
Jazz Pharmaceuticals PLC is a biotechnology company. The Company is engaged in developing medicines for people with serious diseases. The Company’s lead marketed products include Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution, Xyrem (sodium oxybate) oral solution, Epidiolex (cannabidiol) oral solution, Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn), Zepzelca (lurbinectedin), Defitelio (defibrotide sodium) AND Vyxeos (daunorubicin and cytarabine) liposome for injection. The Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution product is for the treatment of cataplexy or excessive daytime sleepiness (EDS), in patients with narcolepsy seven years of age and older. The Xyrem (sodium oxybate) oral solution product is for the treatment of cataplexy or EDS in patients with narcolepsy seven years of age and older. The Defitelio (defibrotide sodium) product is for the treatment of hepatic veno-occlusive disease (VOD).